KACD
Articles
- Page Path
- HOME > Restor Dent Endod > Volume 42(1); 2017 > Article
- Open Lecture on Statistics Statistical notes for clinical researchers: Risk difference, risk ratio, and odds ratio
- Hae-Young Kim
-
2017;42(1):-76.
DOI: https://doi.org/10.5395/rde.2017.42.1.72
Published online: January 9, 2017
Department of Health Policy and Management, College of Health Science, and Department of Public Health Sciences, Graduate School, Korea University, Seoul, Korea. JFIF d d Ducky d qhttp://ns.adobe.com/xap/1.0/ |er˭|I|-fGK.rΛp8XV1%K6mvG+tc+qE &ǸC_Nm:l=_/m5^[dߌڇ.c<%:)tQ$Ow~-aY;UJ >=F)2[nk؆?훐 M=l6[4(O.]2#-H^n#->&mp5~Fӛ+|| S,xag% qkEUzUgæBhߕP(7]kFnq?֖Cpru Z6*rEڊtS|*tI*E}7R<,nUU֫^I7Q*mSly%rdȓd8hE<9oHhMfNSRj[i7D[Rj݊+kდq{"$$H?p \̅S?㭻;t~ R߁ )^/>Qj`yt[w ԛ;² ~+ ߔ_ YW~|o] ?x^ᯛ `ʼn;g)T@vWn]>&4l p+$D̢1l|ȨF%-} .9[}w~
ԠLM9hСablfe&QoW !s ?wjLK?s7yO>(=C~_nyǜu? v 3vyo oI@qV-jeES^[9WoSܝh"l2C1a͔CiJ@3:Pճw= /7ovuk+\V;lDgն <[A+r X~d;m!_s8ݖ;;.0llUC+?i#_crʙ1~C.\q u l8Hܶ2m`ܻM3Tov|Bs rɵ"oLS-
DКw=Tv@f '6|YlD͓Y%-#Ѯo%:&!3o%\J<02;K87>^vgƓ# ;ݝmz^Y6=PS39U%~
&f#
}o!muH; ʲŇ˷yvP+&.7e[3'vR4Yj̗IZ`e˽3o[WU{
m[sUbۋZǾۆl6~9'V*.\S2<Sd*zY[aŶ`]C$n.v^Ʌ
dng>ەZ,Mmϑ :n6nϦezW qUJ4! ۇ4R! =>>F n|Q[{pRO 17ƕ~._I ''00k=b՛o}Osðc2'o\3}ݭQ^ 2 . R1yKȣtAݿ-u ܾw!`?1Whn|gzU o[ECWwjUIן)^h#1ɭ!/Z
np;o;ΗŻkXs."6E`Z1
עӐ9Kl8qd q} 2Stt;#j>;խabONŗ=fwP1j)l6J̶|gV 2`y/0E˛6+ԫ1?
6}KW c\KoKͨ2ۅFws*TԞLיuDx .kCzWXhy۶gLu|%TnupǺl-S* P RaLnT+c+*xl.v!.U=|; !_L̎뱚U=4hm:ٯ"y)$:>%(n}X'p[ȴ
^˒4kƓmzDx
\
'Nq amP7nyN݅=
- Correspondence to Hae-Young Kim, DDS, PhD. Associate Professor, Department of Health Policy and Management, College of Health Science, and Department of Public Health Sciences, Graduate School, Korea University, 145 Anam-ro, Seongbukgu, Seoul, Korea 02841. TEL, +82-2-3290-5667; FAX, +82-2-940-2879; kimhaey@korea.ac.kr
©Copyrights 2017. The Korean Academy of Conservative Dentistry.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
- 4,877 Views
- 54 Download
- 31 Crossref
In the previous section, we discussed risk and odds. Both risk and odds can be applied to a cohort study designs based on population. On the other hand, a case-control study is not based on population but designed by separate sampling procedures in the disease group and no disease group. Therefore, there is no denominator to estimate the risk in the entire population and only odds can be obtained in the case-control design. Regarding those study designs, we'll talk about definitions, applicability, difference, and interpretation of risk difference (RD), risk ratio (RR), and odds ratio (OR) as measures of effects in studies with cohort and case-control design.
Definition
RD or AR is defined as the difference in risk of a condition such as a disease between an exposed group and an unexposed group (Table 1).
RR is the ratio between the risk of exposed group and unexposed group.
OR is the ratio between odds of exposed group and unexposed group.
Risk difference, risk ratio, and odds ratio as measures of effects in cohort design
A cohort study design pursues the effect of exposure such as treatment, prospectively. In the cohort study, we extract an adequate size of a random sample from the target population, then randomly assign the subjects into either the expose group or unexposed group. The effect of exposure is observed as the changes in outcome of interest over time. Risk is easily calculated as the number of persons having the disease in exposed and unexposed groups divided by the number of all the persons in both groups. In the cohort study, we have a clear denominator: the number of persons assigned in the groups. RD and RR are frequently used to assess the association between the exposed and control groups. RD, which is also known as AR or excessive risk, represents the amount of risk, which decreased or increased when the exposure exists compared to that when the exposure is absent. A positive RD value means increased risk and a negative one means decreased risk by the exposure. RR is calculated as the risk of an exposed group divided by the risk of an unexposed group. A RR value of 1 means no difference in risk between groups, and larger or smaller values mean increased or decreased risk in an exposed group compared to the risk in an unexposed group, which can be interpreted that the occurrence of disease is more or less likely in the exposed group, respectively.
In addition, we can also use OR for the same purpose in cohort studies. OR is the ratio of odds of disease in an exposed group and an unexposed group. The interpretation OR is not as intuitive as RR. An OR value of 1 means no difference in odds between groups, and larger value than 1 means increased odds in exposed group, interpreted as a positive association between having disease and having exposure. Contrarily an OR value of smaller than 1 means decreased odds in exposed group which is interpreted as the association between having disease and not having exposure. Though the interpretation of OR is similar to that of RR, they have similar values only when risks of both groups are very low, e.g., p < 0.1. Otherwise, they show different values. As seen in Table 2, the values of RR and OR are approximately the same only when risk of both groups are very low (p < 0.1, Examples 1 - 5 in Table 2). However, when risks of either one or both groups are not very low (p > 0.1), there are considerable discrepancy between RR and OR values (Examples 6 - 14, Table 2). A general rule is that a value of OR is always reflecting larger effect size or stronger association, by showing smaller OR values than corresponding RR values when RR < 1 and larger OR values when RR > 1. In Table 2, we can confirm that all the cases with RR larger than 1 had much larger OR values (Examples 6 - 8 and 10 - 14), and a case with RR smaller than 1 had a smaller OR value than the corresponding RR value (Example 9). Therefore, incorrect interpretation of OR value as RR will lead to an overstatement of the effect by either erroneously increasing or decreasing the true risks. Figure 1 depicts that the differences between OR and RR values get larger as the levels of baseline risk in the control group (I0) increase.1 Especially when baseline risk is as large as 0.5, the maximum RR value is confined to 2, while OR value approaches infinity.
OR has been used as a very popular estimate of effect in epidemiological studies. As the logistic regression has been frequently used in multivariate assessment of binary outcomes, OR which is the exponentiated regression coefficient from logistic regression has been popular, too. The logistic regression has a computational advantage that the convergence is efficient because the related logit link can convert risk (p) values, confined from 0 to 1, into log odds values ranging from negative infinity to positive infinity. Fortunately, lots of life-threatening diseases tend to have very low risk (or prevalence), e.g., lower than 0.1, therefore use of OR can be justified as a good estimator of RR. However, when we analyze data of prevalent diseases such as dental caries or periodontitis, we need to be careful not to interpret the strong association by OR as if it is by RR. Because the OR value is far from 1 than the corresponding RR value when the disease is not rare, to avoid possible mistake of overstating the effect, the resulting OR value can be converted into RR using following equation only when baseline risk can be appropriately assumed:
, where I0 is baseline risk of control group.2
When the outcome is not rare, Poisson regression or log-binomial model are preferred to obtain RR instead of logistic regression.
Odds ratio as the measure of effects in case-control designs
When we are interested in a disease that is very rare, implementing a study with a cohort design is disadvantageous because not only it requires a long observation period and high cost but also it is very difficult to get sufficient information on occurrence of the disease. Case-control design offers a more efficient alternative in such a situation. In case-control design, subjects were selected from disease and no disease groups separately. The sample size of control group without disease is determined as appropriate, only considering the sample size of disease group. Therefore, there is no denominator which is needed to calculate a risk because information on the entire population is not collected. Computing both risk (p) and RR is impossible in the case-control design.
However, odds and OR, ratio of odds in exposed and unexposed group, can be easily obtained in this design. When the disease is very rare, we can use OR as an approximation of RR. Also different size of no disease group is applicable as the study design is needed. Table 3 shows the value of RR can be easily changed by only arbitrarily changing the size of no disease group from 1.91 to 1.98, while OR shows consistency having the same value of 2. Therefore, you should not use risk or RR inappropriately in studies with case-control design. When the outcome of interest has very low prevalence, OR calculated in case-control studies can be used as an approximation of RR.
The procedure of obtaining OR and RR using IBM SPSS Statistics for Windows Version 23.0 (IBM Corp., Armonk, NY, USA)
REFERENCES
Figure 1
Relationship between odds ratio and relative risk at various levels of baseline risks in the control group (I0 = 0.5, 0.3, 0.2, 0.1, 0.05, and 0.01).1 I0, baseline risk of control group.
Table 1
An example of 2*2 cross table showing formulas of risk difference, risk ratio, and odds ratio
Table 2
Comparison of risk difference, risk ratio, and odds ratio based on risks (p) and odds of two competitive groups (assume n = 1,000 per group)
Table 3
Comparison of odds ratio (OR) and relative risk (RR) in two case-control designs with different size of no disease group
Tables & Figures
REFERENCES
Citations
Citations to this article as recorded by 
- AttributeRank: An Algorithm for Attribute Ranking in Clinical Variable Selection
Donald Douglas Atsa'am, Ruth Wario, Pakiso Khomokhoana
Journal of Evaluation in Clinical Practice.2025;[Epub] CrossRef - Safety of RTS,S/AS01E vaccine for malaria in African children aged 5 to 17 months: A systematic review and meta-analysis of randomized controlled trials
Joseph Alexis Zoa, Rahi-metou Njemguie Linjouom, Martin Nyangono Ndongo, Jan Rene Nkeck, Alassane Dicko
PLOS Global Public Health.2025; 5(6): e0004387. CrossRef - Prenatal depression with comorbid diabetes or hypertension and the risk of adverse postnatal maternal health outcomes: a systematic review and meta-analysis
Biruk Beletew Abate, Berihun Assefa Dachew, Getinet Ayano, Kim Betts, Rosa Alati
Journal of Psychosomatic Research.2025; 196: 112341. CrossRef - Variation in coronary revascularisation and mortality after myocardial infarction across three public health insurance schemes in Thailand: an observational analysis from nationwide claims data
Woranan Witthayapipopsakul, Orawan Anupraiwan, Gumpanart Veerakul, Anne Mills, Ipek Gurol-Urganci, Jan van der Meulen
BMJ Public Health.2025; 3(2): e001264. CrossRef - An Evaluation of the Pathways Community HUB Approach To Improving Birth Outcomes: A Retrospective Study Using Propensity Score Matching in Richland, Ohio
Edward T. Chiyaka, Vinay K. Cheruvu, John A. Hoornbeek
Maternal and Child Health Journal.2025; 29(10): 1425. CrossRef - Prenatal depression comorbid with diabetes or hypertension and the risk of adverse neonatal outcomes: A systematic review and meta-analysis
Biruk Beletew Abate, Berihun Assefa Dachew, Getinet Ayano, Kim Betts, Rosa Alati
Annals of Epidemiology.2025; 111: 154. CrossRef - Risk of Cervical Dizziness in Patients With Cervical Spondylosis
Tzu-Pu Chang, Zheyu Wang, Xin-Xian Lee, Yu-Hung Kuo, Michael C. Schubert
JAMA Otolaryngology–Head & Neck Surgery.2024; 150(2): 93. CrossRef - Identifiability and Estimation for Potential-Outcome Means with Misclassified Outcomes
Shaojie Wei, Chao Zhang, Zhi Geng, Shanshan Luo
Mathematics.2024; 12(18): 2801. CrossRef - Reply to: ‘Comment on Kridin et al.—Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis’
Khalaf Kridin, Henner Zirpel, Noor Mruwat, Ralf J. Ludwig, Diamant Thaci
Journal of the European Academy of Dermatology and Venereology.2024;[Epub] CrossRef - Videolaryngoscopy during Urgent Cesarean Delivery: Association with Neonatal Intensive Care Unit Admission
Andrew King, Julie-Ann Thompson, Stewart Hart, Bobby Nossaman
Southern Medical Journal.2024; 117(8): 494. CrossRef - Application of Meta-analysis for Determining Cancer Biomarkers
Halil İbrahim Pazarbaşı, Athanasia Pavlopoulou
Arşiv Kaynak Tarama Dergisi.2024; 33(3): 165. CrossRef - PRACTICAL EXPERIENCE OF USING NANO-SILVER PREPARATIONS IN COMPLEX TREATMENT OF CHILDREN WITH ACUTE ADENOIDITIS
Yuriy V Shevchuk, Zhanna A Tereshchenko
OTORHINOLARYNGOLOGY.2024; : 19. CrossRef - The associations of maternal and paternal obesity with latent patterns of offspring BMI development between 7 and 17 years of age: pooled analyses of cohorts born in 1958 and 2001 in the United Kingdom
William Johnson, Snehal M. Pinto Pereira, Silvia Costa, Jennifer L. Baker, Tom Norris
International Journal of Obesity.2023; 47(1): 39. CrossRef - Treatment with Cinnabsin in patients with acute and exacerbated chronic rhinosinusitis
Rumen Benchev, Dilyana Vicheva
Romanian Journal of Rhinology.2023; 13(52): 165. CrossRef - Bone marrow overexpression of SNAI1 is an early indicator of intrinsic drug resistance in patients with de novo acute myeloid leukemia
Mahmoud B. Y. Gouda, Naglaa M. Hassan, Eman I. Kandil
The Journal of Gene Medicine.2023;[Epub] CrossRef - Social support and psychosocial well-being among older adults in Europe during the COVID-19 pandemic: a cross-sectional study
Ji Lu, Juyang Xiong, Shangfeng Tang, Ghose Bishwajit, Shuyan Guo
BMJ Open.2023; 13(7): e071533. CrossRef - Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia
N. A. Avxentyev, Yu. V. Makarova
FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology.2023; 16(3): 375. CrossRef - Stereotactic radiosurgery for cerebellopontine meningiomas: a systematic review and meta-analysis
Julian L. Gendreau, Kristin Sheaffer, Nicholas Macdonald, Caitlin Craft-Hacherl, Mickey Abraham, Nitesh V. Patel, Yehuda Herschman, James G. Lindley
British Journal of Neurosurgery.2023; 37(2): 199. CrossRef - Therapeutic Exercises and Modalities in Athletes With Acute Hamstring Injuries: A Systematic Review and Meta-analysis
Amornthep Jankaew, Jih-Ching Chen, Samatchai Chamnongkich, Cheng-Feng Lin
Sports Health: A Multidisciplinary Approach.2023; 15(4): 497. CrossRef - Flare-ups After Nonsurgical Retreatments: Incidence, Associated Factors, and Prediction
Ali Nosrat, Michael Valancius, Sahar Mehrzad, Omid Dianat, Prashant Verma, Anita Aminoshariae, Ashraf F. Fouad
Journal of Endodontics.2023; 49(10): 1299. CrossRef - Prevalence of mental health problems among children with long COVID: A systematic review and meta-analysis
Nurulhuda Mat Hassan, Hani Syahida Salim, Safiya Amaran, Nurul Izza Yunus, Nurul Azreen Yusof, Norwati Daud, Deborah Fry, Omar Enzo Santangelo
PLOS ONE.2023; 18(5): e0282538. CrossRef - Analysis of Airway Management for Cesarean Delivery: Use of Risk and Proportion Differences
Andrew King, Justin Morello, Allison Clark, Adrienne Ray, Colleen Martel, Roneisha McLendon, Anne McConville, Melissa Russo, Liane Germond, Bobby Nossaman
Southern Medical Journal.2022; 115(3): 198. CrossRef - Pathogenetic Significance of YBX1 Expression in Acute Myeloid Leukemia Relapse
Mahmoud B.Y. Gouda, Naglaa M. Hassan, Eman I. Kandil, Riham Abdel-Hamid Haroun
Current Research in Translational Medicine.2022; 70(3): 103336. CrossRef - Is the clinical performance of composite resin restorations in posterior teeth similar if restored with incremental or bulk-filling techniques? A systematic review and meta-analysis
Patrícia Valéria Manozzo Kunz, Letícia Maíra Wambier, Marina da Rosa Kaizer, Gisele Maria Correr, Alessandra Reis, Carla Castiglia Gonzaga
Clinical Oral Investigations.2022; 26(3): 2281. CrossRef - Expression and prognostic significance of chromatin modulators EHMT2/G9a and KDM2b in acute myeloid leukemia
Mahmoud B. Y. Gouda, Mohammed A. Zidane, Abdelhady Sayed Abdelhady, Naglaa M. Hassan
Journal of Cellular Biochemistry.2022; 123(8): 1340. CrossRef - Antimicrobial-associated organ injury among the elderly: a systematic review and meta-analysis protocol
Tichawona Chinzowu, Sandipan Roy, Prasad S Nishtala
BMJ Open.2022; 12(2): e055210. CrossRef - Bankruptcy among insured surgical patients with breast cancer: Who is at risk?
Samilia Obeng‐Gyasi, Lava R. Timsina, Oindrila Bhattacharyya, Carla S. Fisher, David A. Haggstrom
Cancer.2021; 127(12): 2083. CrossRef - Risk of Infection after Deep Brain Stimulation Surgery with Externalization and Local-Field Potential Recordings: Twelve-Year Experience from a Single Institution
Lucia K. Feldmann, Wolf-Julian Neumann, Katharina Faust, Gerd-Helge Schneider, Andrea A. Kühn
Stereotactic and Functional Neurosurgery.2021; 99(6): 512. CrossRef - Predicting Retention in HIV Primary Care: Is There a Missed Visits Continuum Based on Patient Characteristics?
Emma Sophia Kay, Ashley Lacombe-Duncan, Rogério M. Pinto
AIDS and Behavior.2019; 23(9): 2542. CrossRef - Prediction of running-induced Achilles tendinopathy with pain sensitivity – a 1-year prospective study
René B.K. Brund, Sten Rasmussen, Uwe G. Kersting, Lars Arendt-Nielsen, Thorvaldur Skuli Palsson
Scandinavian Journal of Pain.2019; 19(1): 139. CrossRef - Heart Rate and Bone Mineral Density in Older Women with Hypertension: Results from the Korea National Health and Nutritional Examination Survey
Mi‐Hyang Jung, Ho‐Joong Youn, Sang‐Hyun Ihm, Hae Ok Jung, Kyung‐Soon Hong
Journal of the American Geriatrics Society.2018; 66(6): 1144. CrossRef
ePub Link
Cite
XML DownloadStatistical notes for clinical researchers: Risk difference, risk ratio, and odds ratio
Figure 1 Relationship between odds ratio and relative risk at various levels of baseline risks in the control group (I0 = 0.5, 0.3, 0.2, 0.1, 0.05, and 0.01).1 I0, baseline risk of control group.
Figure 1
Statistical notes for clinical researchers: Risk difference, risk ratio, and odds ratio
An example of 2*2 cross table showing formulas of risk difference, risk ratio, and odds ratio
| Exposure | No exposure | Total | |
|---|---|---|---|
| Disease | a | b | a + b |
| No disease | c | d | c + d |
| Total | a + c | b + d | a + b + c + d |
| Risk (of disease) | a / (a + c) | b / (b + d) | |
| Odds | a / c | b / d | |
| Risk difference (RD) | (a / [a + c]) - (b / [b + d]) | ||
| Risk ratio (RR) | (a / [a + c]) / (b / [b + d]) | ||
| Odds ratio (OR) | (a / c) / (b / d) |
Comparison of risk difference, risk ratio, and odds ratio based on risks (p) and odds of two competitive groups (assume n = 1,000 per group)
| No. of event | Risk (p) | Odds | Risk difference | Risk ratio | Odds ratio | ||||
|---|---|---|---|---|---|---|---|---|---|
| Example | Control | Tx. | Control (1) | Tx. (2) | Control (3) | Tx. (4) | (2) - (1) | (2) / (1) | (4) / (3) |
| 1 | 1 | 2 | 0.001 | 0.002 | 0.001 | 0.002 | 0.001 | 2.000 | 2.000 |
| 2 | 5 | 10 | 0.005 | 0.010 | 0.005 | 0.010 | 0.005 | 2.000 | 2.000 |
| 3 | 10 | 20 | 0.010 | 0.020 | 0.010 | 0.020 | 0.010 | 2.000 | 2.000 |
| 4 | 15 | 30 | 0.015 | 0.030 | 0.015 | 0.031 | 0.015 | 2.000 | 2.067 |
| 5 | 50 | 100 | 0.050 | 0.100 | 0.053 | 0.111 | 0.050 | 2.000 | 2.096 |
| 6 | 100 | 200 | 0.100 | 0.200 | 0.111 | 0.250 | 0.100 | 2.000 | 2.252 |
| 7 | 200 | 400 | 0.200 | 0.400 | 0.250 | 0.667 | 0.200 | 2.000 | 2.668 |
| 8 | 200 | 700 | 0.200 | 0.700 | 0.250 | 2.333 | 0.500 | 3.500 | 9.333 |
| 9 | 500 | 200 | 0.500 | 0.200 | 1.000 | 0.250 | −0.300 | 0.400 | 0.250 |
| 10 | 500 | 600 | 0.500 | 0.600 | 1.000 | 1.500 | 0.100 | 1.200 | 1.500 |
| 11 | 500 | 700 | 0.500 | 0.700 | 1.000 | 2.333 | 0.200 | 1.400 | 2.333 |
| 12 | 500 | 990 | 0.500 | 0.990 | 1.000 | 99.00 | 0.490 | 1.980 | 99.00 |
| 13 | 900 | 950 | 0.900 | 0.950 | 9.000 | 19.00 | 0.050 | 1.060 | 2.111 |
| 14 | 998 | 999 | 0.998 | 0.999 | 499.0 | 999.0 | 0.001 | 1.001 | 2.002 |
Comparison of odds ratio (OR) and relative risk (RR) in two case-control designs with different size of no disease group
| Disease | No disease | Total | Disease | No disease | Total | ||
|---|---|---|---|---|---|---|---|
| Exposure | 10 | 100 | 110 | Exposure | 10 | 500 | 510 |
| No exposure | 5 | 100 | 105 | No exposure | 5 | 500 | 505 |
| OR = (10/100) / (5/100) = 2.00 | OR = (10/500) / (5/500) = 2.00 | ||||||
| RR = (10/110) / (5/105) = 1.91 | RR = (10/510) / (5/505) = 1.98 | ||||||
Table 1 An example of 2*2 cross table showing formulas of risk difference, risk ratio, and odds ratio
Table 2 Comparison of risk difference, risk ratio, and odds ratio based on risks (p) and odds of two competitive groups (assume n = 1,000 per group)
Table 3 Comparison of odds ratio (OR) and relative risk (RR) in two case-control designs with different size of no disease group
